行情

COLL

COLL

Collegium Pharm
NASDAQ

实时行情|Nasdaq Last Sale

21.06
+0.78
+3.85%
盘后: 21.06 0 0.00% 16:08 12/06 EST
开盘
20.52
昨收
20.28
最高
21.20
最低
20.25
成交量
25.11万
成交额
--
52周最高
22.28
52周最低
10.01
市值
7.06亿
市盈率(TTM)
-62.1422
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

COLL 新闻

  • Hedge Funds Love Unisys Corporation (UIS) Way More Than These 4 Stocks
  • Insider Monkey.9小时前
  • Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits
  • Seeking Alpha - Article.3天前
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.3天前
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.3天前

更多

所属板块

制药
+0.53%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

COLL 简况

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
展开

Webull提供Collegium Pharmaceutical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。